Original Research
Published on 11 Dec 2025
Glymphatic dysfunction in neuromyelitis optica spectrum disorder
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1698986
- 1,901 views
Type at least 3 characters
1,510 articles
articles
Review
Published on 11 Dec 2025
Brain TRPV1 channel-mediated calcium influx: the immunomodulatory pathway of acupuncture in neuroinflammation
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1700282
- 1,762 views
Original Research
Accepted on 09 Dec 2025
Neuronal autoantibodies associated with poorer neuropsychological and motor outcomes 6 months after stroke: Results from the PHYS-STROKE trial
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
- 355 views
Original Research
Published on 09 Dec 2025
Brain-infiltrated monocyte macrophages in a rat model of temporal lobe epilepsy: revisiting the pro-inflammatory paradigm
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1695856
- 1,315 views
Original Research
Published on 08 Dec 2025
Autoimmune cerebellopyramidal syndrome as a complex form of autoimmune cerebellar ataxia: a cohort study
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1724439
- 845 views
Systematic Review
Published on 05 Dec 2025
Visualized knowledge mapping on the current research trends and emerging areas of neuroimmune modulation in the past two decades
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1671578
- 1,561 views
Opinion
Published on 03 Dec 2025
Beyond the cut-off: harmonizing kappa free light chain index using likelihood ratios improves the clinical interpretation in the diagnosis of multiple sclerosis
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1672662
- 1,008 views
Review
Published on 03 Dec 2025
Dual role of complement in neuronal repair
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1712452
- 1,697 views
Original Research
Published on 01 Dec 2025
Reduced CD40 expression in B cell subsets of individuals with radiologically isolated syndrome
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1680233
- 1,225 views
Original Research
Published on 21 Nov 2025
Modeling lymphocyte subset dynamics after ublituximab therapy in patients with multiple sclerosis: an Italian prospective study
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1688090
- 1,949 views
Review
Published on 20 Nov 2025
The critical role of Th17 cells and IL-17A in autoimmune and inflammation-associated neurological diseases: mechanisms and therapeutic perspectives
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1656422
- 3,951 views
- 1 citation
Mini Review
Published on 20 Nov 2025
Neuroimmune modulatory effects of the NLRP3 inflammasome: the role of sex and living environment in brain affecting conditions
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1711656
- 2,038 views
Review
Published on 20 Nov 2025
Decoding tRNA dynamics in neuroimmune disorders: mechanistic insights, diagnostic innovations, and therapeutic opportunities
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1642370
- 1,971 views
Correction
Published on 20 Nov 2025
Correction: Polysialic acid restrains inflammatory monocyte maturation
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1731973
- 802 views
Original Research
Published on 19 Nov 2025
Natalizumab and fumarate treatment differentially modulate CD4+ T cell and B cell subtypes in multiple sclerosis patients without impacting durable COVID-19 vaccine responses
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1568157
- 1,871 views
Review
Published on 19 Nov 2025
Vaccination and COVID-19: impact on long-COVID
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1686572
- 3,048 views
Original Research
Published on 11 Nov 2025
Genetic knockdown of DYRK1A attenuates cognitive impairment, Aβ pathology, tauopathy and neuroinflammatory responses in mouse models of AD
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1661791
- 2,933 views
- 1 citation
Original Research
Published on 07 Nov 2025
Prognostic value of kappa free light chain index in patients with primary progressive multiple sclerosis
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1658182
- 2,260 views
Original Research
Published on 04 Nov 2025
Sex differences in abnormal gluten response and predictors of gluten sensitivity in patients with schizophrenia
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1696763
- 1,365 views
Review
Published on 30 Oct 2025
The mechanisms of specialized pro-resolving mediators in pain relief: neuro-immune and neuroglial regulations
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1634724
- 3,420 views
- 1 citation
Original Research
Published on 29 Oct 2025
Antibodies to myelin oligodendrocyte glycoprotein in optic perineuritis
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1657600
- 1,332 views
Original Research
Published on 28 Oct 2025
Intestinal mucosal alterations parallel central demyelination and remyelination: insights into the gut-brain axis in the cuprizone model of multiple sclerosis
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1682183
- 3,079 views
Original Research
Published on 27 Oct 2025
The ATP-mediated cytokine release by macrophages is down-modulated by unconventional α9* nicotinic acetylcholine receptors
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1661114
- 2,370 views
Brief Research Report
Published on 27 Oct 2025
Combination therapy of ofatumumab and daratumumab in patients with severe anti-NMDA receptor encephalitis
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1681884
- 1,753 views